Dr. Matthew Thompson, who has served as chief medical officer at Endologix since 2016, has been promoted to CEO of the vascular disease treatments company.
Richard Mott, who has been serving as interim CEO, will return to his role as executive chair of the company’s board of directors, Endologix announced November 10.
On top of his CMO duties managing business development, medical affairs, regulatory, clinical, and R&D departments, Thompson led the April 2021 acquisition and integration of PQ Bypass.
“Matt embodies the fusion of the entrepreneurial vision and subject matter expertise that we need to successfully accelerate Endologix as a leader in the development and commercialization of the most innovative devices for the treatment of vascular disease,” Mott said in a news release.
Endologix in 2020 filed for Chapter 11 bankruptcy protection. It agreed at the same time to be purchased by its largest creditor, Deerfield Partners, which took the Irvine, California–based company private.